Literature DB >> 19366566

Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor.

Javier Carbone1, Javier Perez-Rojas, Elizabeth Sarmiento.   

Abstract

Tumor necrosis factor (TNF)-alpha inhibitors (infliximab, adalimumab, and etanercept) used in immune-mediated inflammatory diseases such as rheumatoid arthritis, Crohn's disease, or psoriatic arthritis have the potential to increase the risk of infectious complications. Pulmonary infections are one of the most frequent complications associated with the use of TNF inhibitors. This article provides an overview of the distinct types of infectious pulmonary complications seen in patients using these anticytokine drugs.

Entities:  

Year:  2009        PMID： 19366566     DOI： 10.1007/s11908-009-0034-2

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  48 in total

1.  [Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update].

Authors:  A López-San Román; A Obrador; J Fortún; P Muñoz; M A Gassull
Journal:  Gastroenterol Hepatol       Date:  2006-02       Impact factor: 2.102

Review 2.  TNFalpha blockade in human diseases: an overview of efficacy and safety.

Authors:  Jan Lin; David Ziring; Sheetal Desai; Sungjin Kim; Maida Wong; Yael Korin; Jonathan Braun; Elaine Reed; David Gjertson; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-04       Impact factor: 3.969

Review 3.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

Review 4.  Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.

Authors:  Anja Strangfeld; Joachim Listing
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-12       Impact factor: 4.098

5.  Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

6.  Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

Authors:  Frederick Wolfe; Kaleb Michaud; Janice Anderson; Kathy Urbansky
Journal:  Arthritis Rheum       Date:  2004-02

7.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

Review 8.  [Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis--efficacy evaluation, adverse effect detection, and prediction of clinical response].

Authors:  Masahiro Yamamura
Journal:  Nihon Rinsho       Date:  2007-07

9.  Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.

Authors:  Dario Ponce de Leon; Eduardo Acevedo-Vasquez; Sergio Alvizuri; Cesar Gutierrez; Mariano Cucho; Jose Alfaro; Risto Perich; Alfredo Sanchez-Torres; Cesar Pastor; Cesar Sanchez-Schwartz; Mariela Medina; Rocio Gamboa; Manuel Ugarte
Journal:  J Rheumatol       Date:  2008-04-01       Impact factor: 4.666

Review 10.  Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.

Authors:  Ryuji Koike; Tsutomu Takeuchi; Katsumi Eguchi; Nobuyuki Miyasaka
Journal:  Mod Rheumatol       Date:  2007-12-20       Impact factor: 3.023
View more
  1 in total

1.  Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation.

Authors:  Violet R Mukaro; Alex Quach; Michelle E Gahan; Bernadette Boog; Zhi H Huang; Xiuhui Gao; Carol Haddad; Suresh Mahalingam; Charles S Hii; Antonio Ferrante
Journal:  Nat Commun       Date:  2018-04-10       Impact factor: 14.919
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.